• Nitra

  Participated · Series B · Mar 2026

  Nitra embeds AI agents into core business functions—payments, procurement, inventory management, scheduling, and insurance verification—giving medical practices a single system to run their back office. Its financial suite includes a Visa-powered expense card, bill pay, patient payment processing, and AI-driven accounting, while its commerce marketplace connects users to thousands of biopharma and medical-supply products through partners like McKesson and Medline. Recently the company added a voice-AI patient management module that handles appointment scheduling and insurance eligibility checks. In 2025 the platform’s annualized revenue jumped from $4 million to more than $33 million on 740 percent growth, and it surpassed $1 billion in annualized processing volume across thousands of doctors in over 700 clinics. December 2025 saw a single-day record of roughly $9 million in purchases. Management expects to serve 3,000+ clinics, top $150 million in annualized revenue, and exceed $4 billion in processing volume during 2026. Founded in 2024 by CEO Tim Hwang and President Jonathan Chen, Nitra plans to expand headcount from about 50 to over 200 and roll out new AI modules for revenue-cycle management, patient marketing, payroll, and staffing.

• Insilico Medicine

  Participated · Series C · Jun 2021

  Insilico Medicine develops Pharma.AI, a generative AI platform that spans biology, generative chemistry, clinical medicine and research and integrates LLM-powered engines such as Nach01 and Dora. The company operates Life Star1, a fully robotic lab that includes a bipedal humanoid AI Scientist to automate and optimize research workflows. Insilico has built a wholly-owned discovery portfolio of 30 assets, with 10 assets having received IND clearance, and its lead candidate Rentosertib has completed a Phase IIa trial showing favorable safety and a dose-dependent FVC response. The company reports it can nominate preclinical candidates in 12–18 months and synthesize/test 60–200 molecules per program, reflecting accelerated early-stage discovery. Insilico also generates sustainable revenue through out-licensing agreements (collectively valued at over $2.1 billion) and collaborations (collected value over $1.4 billion), with milestone payments contributing to financial performance. Future plans announced include refining AI models and algorithms, expanding and updating its automated lab, advancing clinical validation of its flagship IPF candidate, and accelerating other in-house and co-developed pipelines. Insilico Medicine is a clinical-stage, end-to-end AI-driven drug discovery company led by founder and CEO Alex Zhavoronkov. The company develops AI platforms that connect biology, chemistry, and clinical-trials analysis using deep generative models, reinforcement learning, transformers, and other machine-learning techniques. Its platforms are used to discover novel targets and design molecular structures with desired properties across oncology, fibrosis, immunity, central nervous system, and aging-related diseases. Insilico says it will use the new funding to accelerate its internal programs and to apply its platform to uncover more novel therapeutics. The company recently announced promising preclinical candidates for COVID-19 (and related variants) and for ALS. Insilico is headquartered in Hong Kong and sources R&D and management resources across the USA, Belgium, Russia, the UK, Taiwan, and China. Insilico Medicine builds an AI-driven drug discovery platform that identifies new targets and molecules and also develops its own therapeutics across fibrosis, immunology, oncology and CNS. The company began as a discovery-focused business and, since 2019, has been advancing in-house drug programs, nominating eight preclinical candidates since 2021. It generates revenue from R&D collaborations (including upfronts and milestones) and customer subscriptions to its platform. Insilico is in the R&D stage, is not yet profitable, and employs about 200 people across six countries and regions. The firm plans to use new capital to fund Phase I studies, further develop its AI platform, and pursue global expansion and strategic initiatives such as a robotic drug discovery laboratory and a robotic biological data factory. A prototype robotic lab is planned for Suzhou and will include AGVs and a phenotyping partnership with X-Imaging. Insilico Medicine operates AI platforms (PandaOmics for target discovery and Chemistry42 for molecule design) to accelerate drug discovery and reduce guesswork in target-to-molecule development. The company demonstrated a proof-of-concept by identifying a novel target for idiopathic pulmonary fibrosis and designing a candidate that progressed through animal studies. That IPF project condensed preclinical development to about 18 months at a cost of roughly $2.6 million, and Insilico says it has 16 therapeutic assets across programs. The company is filing an investigational new drug (IND) application with the FDA, plans to begin human dosing this year, and aims to start a clinical trial late this year or early next year. Insilico has collaborated with Pfizer, Johnson & Johnson, Taisho Pharmaceuticals, and announced a new partnership with Teva to use PandaOmics. Insilico Medicine is a Hong Kong-based developer of next-generation AI for drug discovery that applies deep learning across the drug discovery and development process. Its core technologies include generative chemistry and target-identification platforms, and the company collaborates with biopharmaceutical firms using disease-relevant assays to validate solutions and generate machine-learnable data. Insilico has identified promising targets across cancer, fibrosis, NASH, immunology and CNS. The company completed a $37M Series B financing to support commercialization and pipeline advancement. It plans to use the funds to commercialize its validated generative chemistry and target-identification technology, build a senior management team with pharmaceutical experience, and further develop and partner on specific therapeutic programs.

• SEA Limited

  Participated · Equity · May 2017

  Sea Limited (f.k.a. Garena Interactive Holding) is a Singapore-based consumer Internet company led by Founder, Chairman, and CEO Forrest Li. The company operates three main platforms: Garena (a digital entertainment platform providing mobile and PC online games across Greater Southeast Asia), Shopee (a mobile-centric e-commerce marketplace), and AirPay (a digital financial services platform). Sea focuses on Southeast Asian markets including Indonesia, Taiwan, Vietnam, Thailand, the Philippines, Malaysia and Singapore, which collectively had 585.5 million people and US$3.0 trillion of GDP in 2016. The company said it will invest the majority of the new capital in the growth of its e-commerce platform Shopee, with a focus on key markets such as Indonesia. In addition to the funding, Sea appointed senior advisors including former Singapore Foreign Minister George Yeo, former Indonesia Minister of Trade Mari Pangestu, and Pandu Sjahrir as Chairman (President Commissioner) of its Indonesia operations. The company’s strategy centers on expanding Shopee while maintaining its digital entertainment and payments offerings across the region.

• ACT Genomics

  Participated · Series B · May 2016

  ACT Genomics, founded in 2014 and led by CEO Dr. Hua Chien Chen, offers DNA sequencing-based cancer solutions across Asia. Its core product is a Next Generation Sequencing (NGS) platform supported by an Asian genome database, a professional bioinformatics and biomedical team, medical reporting, and integrated services. The company's flagship NGS panel, ACTOnco®+, investigates 440 cancer-related genes using a signaling-pathway design to provide optimal treatment suggestions. ACTOnco®+ recommends targeted therapies, hormonal therapies, chemotherapies, and immunotherapies for all solid tumor types. ACT Genomics has operations in Taiwan, Hong Kong, Singapore and Japan and has established a joint venture with Canon Medical System Corporation in Japan to operate cancer genomic profiling services and sequencing data analysis. The company recently closed an equity financing of an undisclosed amount and intends to use the funds to strengthen its presence and capabilities across the Pan-Asia region. ACT Genomics is an integrated cancer molecular information company based in Taipei, Taiwan. It provides comprehensive genomic profiling assays and molecular information to physicians and biopharmaceutical customers, along with clinical services. Its offerings help expand targeted therapy treatment options, predict response to immune-checkpoint inhibitors, and utilize ctDNA-based assays to monitor tumor burden and resistant markers. These tests are performed in a CAP-accredited NGS laboratory. The company raised US$12.5M in a Series B and will use the proceeds to boost capacity and ramp up commercial channels to support growth and expansion across Japan, Taiwan, Singapore, Malaysia, Thailand and Hong Kong. ACT Genomics plans to drive further global expansion following its move into the Asia Pacific region earlier this year.

• Eden Biologics

  Participated · Series B · Jun 2014

  JHL Biotech focuses on developing and manufacturing affordable biologic medicines, with an emphasis on biosimilars, bioengineering and innovative manufacturing solutions. The company provides process development and cGMP manufacturing services and helps global partners access the China market. JHL's pipeline includes proprietary biosimilar compounds and a pre-clinical novel therapeutic portfolio. The company plans to use new funding to continue biosimilar programs through clinical trials, construct a fill-finish facility at its Wuhan commercial manufacturing plant, expand its pre-clinical novel therapeutic portfolio, and support working capital. With the Series C proceeds, JHL has secured capital necessary to complete full development and BLA filing of at least two of its proprietary biosimilar compounds. Founded in 2012 and led by President and CEO Racho Jordanov, the company is based in Hsinchu. Founded in December 2012 and led by President and CEO Racho Jordanov, JHL Biotech focuses on bioengineering and product development under current Good Manufacturing Practices (cGMP). The company has five biosimilar programs and one new molecular entity in development, with an emphasis on biosimilar monoclonal antibodies. It completed construction of a clinical manufacturing facility in Hsinchu, Taiwan in December 2013 and has formed partnerships with domestic academic and government institutions as well as regional and global biotech and pharmaceutical companies. JHL plans to submit its first clinical trial and investigational new drug (IND) applications in 2015. Financially, it closed a $35M Series B to fund development of its biosimilar mAb pipeline, accelerate IND filings, support facility expansion in Taiwan, and acquire equipment for a commercial manufacturing facility in Wuhan, China expected to be completed by 2014 year-end. The financing is intended to support both R&D progress and commercial manufacturing build-out.

No current team members are available.